SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Rob L. who wrote (710)4/16/1998 1:49:00 PM
From: B.Fitz  Read Replies (1) | Respond to of 1580
 
I agree, Growth was good and the future looks good. At these levels I think this is a great buy. I think this is a bit of an over reaction. If the split rumors are correct this will take off.

Fitz



To: Rob L. who wrote (710)4/16/1998 3:20:00 PM
From: Nick  Read Replies (2) | Respond to of 1580
 
Drug maker Merck and Co. (NYSE: MRK) lost $2 15/16 to $120 9/16
after reporting Q1 EPS of $0.95 compared to $0.82 a year ago, which
missed the First Call mean estimate by a penny. Sales growth in the period was hampered by the divestiture of the firm's crop protection unit and foreign exchange costs, which shaved two percentage points from revenue growth alone.

We're losing money today, because of this crop protection stuff? GEEZ!!!!!

Nick


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News